Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ): $163.36

-1.17 (-0.71%)

POWR Rating

Component Grades














  • Stability is the dimension where JNJ ranks best; there it ranks ahead of 96.36% of US stocks.
  • The strongest trend for JNJ is in Growth, which has been heading up over the past 177 days.
  • JNJ's current lowest rank is in the Momentum metric (where it is better than 17.42% of US stocks).

JNJ Stock Summary

  • With a market capitalization of $435,655,108,602, JOHNSON & JOHNSON has a greater market value than 99.84% of US stocks.
  • JNJ's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 3,403.26 -- higher than 99.29% of US-listed equities with positive expected earnings growth.
  • The volatility of JOHNSON & JOHNSON's share price is greater than that of just 0.91% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are UNH, TSM, V, XOM, and WMT.
  • JNJ's SEC filings can be seen here. And to visit JOHNSON & JOHNSON's official web site, go to

JNJ Valuation Summary

  • In comparison to the median Healthcare stock, JNJ's price/sales ratio is 142.11% higher, now standing at 4.6.
  • JNJ's EV/EBIT ratio has moved up 2.2 over the prior 243 months.

Below are key valuation metrics over time for JNJ.

Stock Date P/S P/B P/E EV/EBIT
JNJ 2022-09-23 4.6 5.7 23.9 22.4
JNJ 2022-09-22 4.6 5.7 23.8 22.4
JNJ 2022-09-21 4.5 5.6 23.4 22.0
JNJ 2022-09-20 4.5 5.7 23.6 22.2
JNJ 2022-09-19 4.6 5.7 23.8 22.4
JNJ 2022-09-16 4.6 5.8 24.0 22.5

JNJ Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at 15.52%.
  • Its 4 year net income to common stockholders growth rate is now at 8.81%.
  • The 4 year revenue growth rate now stands at 15.55%.
Over the past 33 months, JNJ's revenue has gone up $13,882,000,000.

The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 95,588 23,582 18,366
2022-03-31 94,880 23,315 19,830
2021-12-31 93,775 23,410 20,878
2021-09-30 91,446 26,021 17,880
2021-06-30 89,190 26,114 17,767
2021-03-31 84,214 24,252 15,115

JNJ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JNJ has a Quality Grade of B, ranking ahead of 92.45% of graded US stocks.
  • JNJ's asset turnover comes in at 0.52 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CBIO, CLSD, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.

The table below shows JNJ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-10-03 0.520 0.675 0.295
2021-07-04 0.514 0.670 0.302
2021-04-04 0.498 0.662 0.273
2021-01-03 0.501 0.656 0.272
2020-09-27 0.504 0.657 0.332
2020-06-28 0.514 0.657 0.307

JNJ Price Target

For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $187.95 Average Broker Recommendation 1.53 (Moderate Buy)

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $163.36 52-week high $186.69
Prev. close $164.53 52-week low $155.72
Day low $163.32 Volume 8,985,100
Day high $165.74 Avg. volume 7,531,931
50-day MA $167.32 Dividend yield 2.77%
200-day MA $172.32 Market Cap 429.50B

Johnson & Johnson (JNJ) Company Bio

Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.

JNJ Latest News Stream

Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

The 3 Best Dividend Stocks to Buy for Retirement

As far as dividend stocks to buy are concerned, these three companies are among the best those heading into retirement should consider.

Chris MacDonald on InvestorPlace | September 29, 2022

10 Best Cheap Dividend Stocks to Buy Now

In this article, we discuss 10 best cheap dividend stocks to buy now. You can skip our detailed analysis of the best dividend stocks and their returns over the years, and go directly to read 5 Best Cheap Dividend Stocks to Buy Now. Inflation and continuous interest rate hikes have brought dividend investing to the […]

Yahoo | September 29, 2022

Is it a Good Move to Trim Your Johnson & Johnson (JNJ) Stake?

Distillate Capital Partners LLC, an investment management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. Through the sharp sell-off in the first half of 2022, Distillate’s U.S. FSV strategy held up better than the overall market with a decline of 15.80% net of fees vs. a 19.96% […]

Yahoo | September 29, 2022

Is Johnson & Johnson a Buy?

The healthcare giant has been a fairly stable investment this year, but does it belong in your portfolio for the long term?

Yahoo | September 29, 2022

Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud

Aligos Therapeutics Inc (NASDAQ: ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson & Johnson (NYSE: JNJ) acquired Alios BioPharma Inc, a privately held infectious disease biotech, for approximately $1.75 billion in cash. Lawrence Blatt and Leonid Beigelman co-founded Alios. Following J&J's 2014 acquisition, Blatt and Beigelman become employees at Janssen. But Blatt and Beigelman left Janssen, starting Aligos Therapeutics Inc (NA

Yahoo | September 29, 2022

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -1.20%
3-mo -8.39%
6-mo -6.21%
1-year 4.49%
3-year 33.81%
5-year 42.04%
YTD -2.63%
2021 11.44%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7487 seconds.